IL-13 Receptor Antagonists for Inflammatory Bowel Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medical treatments for inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis, are inadequate as they either have significant side effects or take too long to show benefits, and there is a need for more effective methods to suppress inflammation and prevent symptoms.
Innovation Solution
Administering a substance that inhibits the binding of IL-13 to IL-13 receptors on T-cells, specifically NKT cells, to modulate IL-13 activity and reduce inflammatory responses, using methods like linking effector molecules to IL-13 receptor binding molecules for targeted delivery and screening for effective substances.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current immunomodulatory medications (e.g., Azathioprine, 6-mercaptopurine, and methotrexate) are used to treat IBD, then the beneficial effects begin to work after as long as three months, but this delays effective treatment and symptom relief
Solution Approach 1:
The patent changes the therapeutic parameter from non-specific immunosuppression to specific IL-13 pathway inhibition. By using anti-IL-13 antibodies or IL-13 receptor antagonists, the treatment targets the specific cytokine responsible for inflammation in IBD, resulting in faster and more effective symptom relief compared to traditional immunomodulators that take months to work.
Solution Approach 2:
The patent introduces IL-13 as the specific intermediary target in the inflammatory pathway. By blocking IL-13 binding to its receptor on T-cells and NKT cells, the treatment interrupts the specific signaling cascade that drives IBD inflammation, providing faster therapeutic effect than broad-spectrum immunomodulators.
2Reliability
If corticosteroids are used to treat IBD, then inflammation in the colon lining is suppressed and symptoms are controlled, but long-term use is not recommended due to side effects
Solution Approach 1:
The patent applies local quality by targeting the specific IL-13 pathway that is locally overactive in IBD inflamed tissue. Rather than using systemic corticosteroids that affect the entire body, the treatment specifically blocks IL-13 signaling in the gastrointestinal tract, providing anti-inflammatory effects without the systemic side effects of long-term steroid use.
Solution Approach 2:
The patent introduces IL-13 receptor antagonists as a specific intermediary that blocks the inflammatory signaling pathway. This targeted approach replaces non-specific corticosteroid-mediated immunosuppression with precise blockade of the IL-13/IL-13R axis, achieving inflammation control without the harmful side effects of long-term steroid therapy.
3Reliability
If aminosalicylates are used to treat ulcerative colitis, then mild to moderate episodes are treated effectively, but they are not effective for severe cases
Solution Approach 1:
The patent changes the therapeutic parameter from mild anti-inflammatory activity (aminosalicylates) to potent cytokine pathway blockade (IL-13 inhibition). By targeting the specific IL-13 pathway with high-affinity antibodies or receptor antagonists, the treatment achieves effectiveness across the full spectrum of disease severity, from mild to moderate and severe cases, unlike aminosalicylates that only work for mild to moderate episodes.
Data Source
AI summary
The present invention provides a method of treating or preventing the inflammatory response of ulcerative colitis or Crohn's disease in a subject comprising administering to the subject an effective amount of a substance that inhibits the binding of IL-13 to IL-13 receptors on NKT cells or delivers an effector molecule to the NKT cells.